Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
test decrease » teer decrease (Expand Search), cost decreased (Expand Search), step decrease (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
test decrease » teer decrease (Expand Search), cost decreased (Expand Search), step decrease (Expand Search)
-
2381
-
2382
Behaviour and significance of reservoir evaporation and seepage losses – an experience of four reservoirs in Damodar River Valley, India
Published 2025“…Annual seepage loss and its mean rate increased gradually for a considerable period during initial operation stage; later, both decreased and stabilized. …”
-
2383
PP1/PP2A does not dephosphorylate pS295 <i>in vitro</i>.
Published 2024“…***<i>P</i> < 0.001 by the unpaired Student’s <i>t</i>-test; n.s., not significant.</p> <p>(TIF)</p>…”
-
2384
-
2385
-
2386
-
2387
-
2388
-
2389
AZ10606120 treatment significantly increased cytotoxicity and reduced cell number in a dose-dependent manner.
Published 2025“…Cell numbers were significantly decreased in cells after treatment with AZ10606120 (50µM) compared to both temozolomide (TMZ; 50µM) treatment and untreated controls. …”
-
2390
Presentation 1_Ceftriaxone-associated dysbiosis decreases voriconazole bioavailability by upregulating intestinal P-glycoprotein expression through activation of the Nrf2-mediated...
Published 2025“…</p>Key findings<p>The diversity and richness of intestinal bacteria, especially the abundance of gram-negative bacteria, were significantly decreased after ceftriaxone treatment. …”
-
2391
Table 1_Ceftriaxone-associated dysbiosis decreases voriconazole bioavailability by upregulating intestinal P-glycoprotein expression through activation of the Nrf2-mediated signall...
Published 2025“…</p>Key findings<p>The diversity and richness of intestinal bacteria, especially the abundance of gram-negative bacteria, were significantly decreased after ceftriaxone treatment. …”
-
2392
-
2393
-
2394
-
2395
-
2396
-
2397
Correlation between immune function indicators and Lymphocyte subsets in pSS patients.
Published 2025Subjects: -
2398
Demographics and clinical features of healthy controls and primary Sjögren’s Syndrome patients.
Published 2025Subjects: -
2399
Correlation between biochemical indicators and Lymphocyte subsets in pSS patients.
Published 2025Subjects: -
2400
Correlation between immune function indicators and Lymphocyte subsets in pSS patients.
Published 2025Subjects: